PAD (peripheral arterial disease) device co closes $25m series B:
This article was originally published in Clinica
Executive Summary
Pathway Medical Technologies, the Redmond, Washington-based developer of the Pathway Atherectomy system for treating peripheral arterial disease (PAD), welcomed two new shareholders this week, following the completion of a $25m series B financing. HLM Venture Partners (Boston, Massachusetts) led the round and Latterell Venture Partners (San Francisco, California) participated together with existing investors ABN AMRO Capital Lifesciences, Giza Ventures and Oxford Bioscience.